Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16673827 | 0.93 | CA2 (0.32) | USP2SMN1; SMN2SIGMAR1CA2CHKA | |
| SCHEMBL6203142 | 0.93 | CA2 (0.35) | USP2SMN1; SMN2SIGMAR1HPGDCA2 | |
| SCHEMBL4046200 | 0.84 | L3MBTL3 (0.33) | SMN1; SMN2HPGDPARP1CHRNB2CHRNA3 | |
| SCHEMBL4594886 | 0.83 | GNAI3 (0.38) | — | |
| SCHEMBL11889891 | 0.83 | CYP1A2 (0.41) | — | |
| SCHEMBL4658596 | 0.82 | CHRM2 (0.33) | SIGMAR1HPGDCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL4434089 | 0.82 | HPGD (0.39) | USP2SMN1; SMN2HPGDCTSKELANE | |
| SCHEMBL5875153 | 0.81 | CA2 (0.41) | SIGMAR1CA2CA12CA1CA9 | |
| SCHEMBL4657727 | 0.81 | — | — | |
| SCHEMBL2373613 | 0.80 | HPGD (0.41) | USP2SMN1; SMN2HPGDCTSKELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | claimed |
| CN-109311863-B | Mutant IDH1 inhibitors | 伊莱利利公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-3464281-B1 | MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| CN-107849059-B | 7-phenylethylamino-4H-pyrimido [4,5-D ] [1,3] oxazin-2-one compounds and their use as inhibitors of mutant IDH1 | 伊莱利利公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-3328866-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3328866-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS | Eli Lilly and Company (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2000041697-A1 | UTILISATION OF 2-SUBSTITUTED 1,2-BENZISOTHIAZOLE DERIVATIVES AND 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES FOR THE PROPHYLAXIS AND THERAPY OF CEREBRAL ISCHAEMIA | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041695-A1 | UTILIZATION OF PYRIMIDINE DERIVATIVES FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| EP-1003752-A1 | 3-SUBSTITUTED 3,4,5,7-TETRAHYDRO-PYRROLO3',4':4,5 THIENO2,3-DPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS 5HT ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999040083-A2 | BIFUNCTIONAL TRYPTASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999040073-A2 | TRYPTASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1999-08-12 | — | — | WO | disclosed |
| EP-0927184-A1 | 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-07 | — | — | EP | disclosed |
| WO-1999021857-A1 | 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHOD FOR PRODUCING THE SAME, AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999020616-A1 | 2-SUBSTITUTED 1,2-BENZISOTHIAZOLE DERIVATIVES AND THEIR USE AS SEROTONIN ANTAGONISTS (5-HT1A, 5-HT1B AND 5-HT1D) | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999007711-A1 | 3-SUBSTITUTED 3,4,5,7-TETRAHYDRO-PYRROLO3',4':4,5 THIENO2,3-DPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS 5HT ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998011110-A1 | 3-SUBSTITUTED PYRIDO[4',3':4,5]THIENO[2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | USP2 1850/4885SMN1; SMN2 1388/4885SIGMAR1 4558/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | USP2 1850/4885SMN1; SMN2 1388/4885SIGMAR1 4558/4885 |
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | IDH1, IDH3A, IDH3B | USP2 2474/4885SMN1; SMN2 1973/4885SIGMAR1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.